France · Question · Question écrite
20001
Question 20001 — pharmacy and medicines
Introduced
—
Last action
—
Status
posée
Sponsors
—
Subjects
Discovery layer
Source updated
—
Summary
Mrs. Agnès Firmin Le Bodo draws the attention of the Minister of Solidarity and Health to the shortage of medicines. Between 2016 and 2017, the number of medicines out of stock increased by more than 30%. Indeed, in 2016, 405 reports were made by pharmacists and more than 530 in 2017. The catastrophic situation that professionals have been experiencing for several weeks cannot continue, it is therefore becoming impossible to respond. provide cortisone which is an essential product for a good number of pathologies. It seems important to point out that the absence of certain medications can result in an extremely serious risk for patients, which can even become life-threatening for some. So, certainly hospitals can give back to certain patients their so-called “city” treatment but have no official directive in this sense and are similarly subject the same shortages. The senator's information report. Jean-Pierre Decool, n° 737 (2017-2018) highlights a problem concerning the waiting period for products which can be up to three months, both for so-called “common” medicines, as well as for medicines of major therapeutic interest and vaccines. Faced with this observation, several factors are pointed out, starting with the problem of approach to raw materials or the sale of medicines in countries in which their selling price is much more advantageous than in France. Furthermore, the modification of marketing authorizations but also the establishment of the just-in-time production system. The simple increase in sales volumes is, moreover, an important factor contributing to this significant shortage of medicines. As can be seen, it becomes crucial to act and launch an ambitious policy to combat drug shortages. She asks him what solutions she is considering to deal with this situation. In addition, she would like to know what resources she will be able to grant to the National Medicines Safety Agency to be the leader of this policy.
Machine translation from French. The official text remains authoritative.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.assemblee-nationale.fr/dyn/15/questions/QANR5L15QE20001
- Open data entity: https://www.assemblee-nationale.fr/dyn/opendata/QANR5L15QE20001